Diatranz Otsuka Limited (DOL) develops cellular therapies through xenotransplantation to improve the lives of people with serious diseases, including type 1 diabetes, and provides testing and consultation services for xenotransplantation programs.

Diatranz Otsuka Limited

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 23, 2024 8:07 PM	1ccdb3d3
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 23, 2024 8:07 PM	7fbc50e1
crunchbase trigger	general	Nov 27, 2024 12:50 PM	dc2a478b
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Oct 23, 2024 8:07 PM	0849ee18
news basic	general	Oct 23, 2024 8:07 PM	060cd39a
bundesanzeiger	filings
financials download nd	financials
private financials	financials

DOLG

COM:DOLGLOBAL

Diatranz Otsuka Limited